First Trust Health Care AlphaDEX Fund
FXH
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 120 East Liberty Drive, Suite 400 Wheaton IL United States of America 60187
- IPO Date
- May 10, 2007
- CIK
- 0001383496
- Website
- ftportfolios.com
- Similar Companies
- Business
- First Trust Health Care AlphaDEX Fund (FXH) is an exchange-traded fund that seeks investment results corresponding generally to the price and yield, before fees and expenses, of the StrataQuant Health Care Index. The fund employs a tiered equal-weighted methodology to track an index comprising approximately 78 large- and mid-cap U.S. health care companies selected and weighted from the Russell 1000 Index using the proprietary AlphaDEX stock selection process, which incorporates fundamental growth and value factors including price momentum, earnings momentum, revised earnings estimates, and quality metrics. Holdings span pharmaceuticals and biotechnology (such as Insmed Incorporated, Tempus AI, Inc., Regeneron Pharmaceuticals, Inc., and Alnylam Pharmaceuticals, Inc.); medical equipment and services (including Zimmer Biomet Holdings, Inc., Boston Scientific Corporation, and Insulet Corporation); and health care providers (like HCA Healthcare, Inc., UnitedHealth Group Incorporated, and Humana Inc.); with top 10 holdings typically accounting for around 24-25% of assets under management. Launched on May 8, 2007 and domiciled in the United States, the fund is issued and managed by First Trust Advisors L.P., with headquarters in Wheaton, Illinois. FXH provides targeted exposure exclusively to the U.S. health care sector for investors seeking enhanced alpha potential through systematic, non-market-cap-weighted selection within this industry, which serves institutional and retail clients focused on health care equities. In recent developments, the fund underwent its scheduled quarterly rebalancing in late 2025, incorporating updated holdings such as increased positions in high-momentum biotech names like Insmed (2.95% weighting) and emerging players like Tempus AI amid sector volatility, while maintaining a total of 78 holdings and assets exceeding $900 million as of late 2025. Performance reflects a year-to-date gain of approximately 11% through December 2025, buoyed by biotech innovations and resilience in health care providers despite broader market pressures, with an expense ratio of 0.62% and quarterly dividend distributions including $0.0616 per share in June 2025. No major acquisitions, partnerships, or structural changes specific to FXH were reported in 2024-2025, though First Trust's broader AlphaDEX suite, including peer funds like the Financials AlphaDEX Fund, executed notable portfolio adjustments such as significant stake increases in select holdings.